[HTML][HTML] Long-lasting severe immune dysfunction in Ebola virus disease survivors
…, H Hocini, C Lefebvre, BP Hejblum, M Durand… - Nature …, 2020 - nature.com
Long-term follow up studies from Ebola virus disease (EVD) survivors (EBOV_S) are lacking.
Here, we evaluate immune and gene expression profiles in 35 Guinean EBOV_S from the …
Here, we evaluate immune and gene expression profiles in 35 Guinean EBOV_S from the …
[PDF][PDF] CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death
Y Lévy, A Wiedemann, BP Hejblum, M Durand… - Iscience, 2021 - cell.com
The identification of patients with coronavirus disease 2019 and high risk of severe disease
is a challenge in routine care. We performed cell phenotypic, serum, and RNA sequencing …
is a challenge in routine care. We performed cell phenotypic, serum, and RNA sequencing …
[PDF][PDF] Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26. ZEBOV/MVA-BN-Filo
F Blengio, H Hocini, L Richert, C Lefebvre, M Durand… - Cell Reports, 2023 - cell.com
Ebola virus disease is a severe hemorrhagic fever with a high fatality rate. We investigate
transcriptome profiles at 3 h, 1 day, and 7 days after vaccination with Ad26.ZEBOV and MVA-…
transcriptome profiles at 3 h, 1 day, and 7 days after vaccination with Ad26.ZEBOV and MVA-…
T Cell immunogenicity, gene expression profile, and safety of four heterologous prime-boost combinations of HIV vaccine candidates in healthy volunteers: Results of …
…, P Tisserand, L Guillaumat, M Durand… - The Journal of …, 2022 - journals.aai.org
Heterologous prime-boost strategies are of interest for HIV vaccine development. The order
of prime-boost components could be important for the induction of T cell responses. In this …
of prime-boost components could be important for the induction of T cell responses. In this …
CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity and death
Y Lévy, A Wiedemann, BP Hejblum, M Durand… - medRxiv, 2020 - medrxiv.org
COVID-19 SARS-CoV-2 infection exhibits wide inter-individual clinical variability, from silent
infection to severe disease and death. The identification of high-risk patients is a continuing …
infection to severe disease and death. The identification of high-risk patients is a continuing …
CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death
Y Lévy, A Wiedemann, BP Hejblum, M Durand… - Iscience, 2023 - cell.com
The authors declare that in their original article, there was an error in the calculation of the
library size for the normalization of some gene expression data. As a result, several figures, …
library size for the normalization of some gene expression data. As a result, several figures, …
Immunologic strategies for HIV-1 remission and eradication
DH Barouch, SG Deeks - Science, 2014 - science.org
Antiretroviral therapy (ART) is able to suppress HIV-1 replication indefinitely in individuals
who have access to these medications, are able to tolerate these drugs, and are motivated to …
who have access to these medications, are able to tolerate these drugs, and are motivated to …
[HTML][HTML] Impact of comprehensive geriatric assessment on survival, function, and nutritional status in elderly patients with head and neck cancer: protocol for a …
…, M Laurent, P Caillet, A Radenne, I Durand-Zaleski… - BMC cancer, 2014 - Springer
Background Survival is poorer in elderly patients with head and neck squamous cell carcinomas
[HNSCCs] than in younger patients. Possible explanations include a contribution of co-…
[HNSCCs] than in younger patients. Possible explanations include a contribution of co-…
Energy expenditure profiles and the risk of early limiting toxicity in older patients with cancer: the ELCAPA-25 prospective cohort survey
…, G Ulmann, G Orvoën, C Chambraud, JP Durand… - Clinical Nutrition, 2022 - Elsevier
Background & aims Predicting the risk of early limiting toxicity (ELT) is major challenge for
the clinician seeking an effective, safe treatment for older patients with cancer. The Cancer …
the clinician seeking an effective, safe treatment for older patients with cancer. The Cancer …
[PDF][PDF] Statistical approaches and methodological developments to optimize clinical vaccine research
L Richert - 2019 - inria.hal.science
… For these, I have supervised Eva Reiner, a biostatistics trainee in my research axis from
March to June 2019, and Mélany Durand (study engineer) who has taken over the analyses …
March to June 2019, and Mélany Durand (study engineer) who has taken over the analyses …